NovoCure Limited (NVCR) Financials

NASDAQ:NVCR

Market Cap

1.94B

Total Revenue

537.84M

Gross Profit

422.97M

Operating Income

-89.52M

Net Income

-92.53M

Metric	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
revenue	10,359,000	15,490,000	33,087,000	82,888,000	177,026,000	248,069,000	351,318,000	494,366,000	535,031,000	537,840,000
costOfRevenue	7,013,000	10,036,000	20,610,000	46,282,000	55,609,000	80,048,000	88,606,000	106,501,000	114,877,000	114,867,000
grossProfit	3,346,000	5,454,000	12,477,000	36,606,000	121,417,000	168,021,000	262,712,000	387,865,000	420,154,000	422,973,000
researchAndDevelopmentExpenses	34,797,000	40,381,000	43,748,000	41,467,000	38,103,000	50,574,000	79,003,000	132,010,000	201,303,000	206,085,000
sellingAndMarketingExpenses	16,406,000	21,177,000	38,861,000	59,449,000	63,528,000	77,663,000	96,675,000	118,017,000	137,057,000	173,658,000
generalAndAdministrativeExpenses	16,602,000	24,052,000	33,864,000	51,007,000	59,114,000	73,456,000	87,948,000	107,437,000	126,127,000	132,753,000
sellingGeneralAndAdministrativeExpenses	33,008,000	45,229,000	72,725,000	110,456,000	122,642,000	151,119,000	184,623,000	225,454,000	263,184,000	306,411,000
operatingExpenses	67,805,000	85,610,000	116,473,000	151,923,000	160,745,000	201,693,000	263,626,000	357,464,000	464,487,000	512,496,000
operatingIncome	-64,459,000	-80,156,000	-103,996,000	-115,317,000	-39,328,000	-33,672,000	-914,000	21,251,000	-44,333,000	-89,523,000
totalOtherIncomeExpensesNet	-157,000	-104,000	-356,000	-396,000	549,000	-398,000	-7,910,000	-3,149,000	-7,742,000	7,677,000
ebitda	-68,486,000	-78,193,000	-103,996,000	-115,317,000	-39,328,000	-33,672,000	-914,000	30,401,000	-44,333,000	-89,523,000
depreciationAndAmortization	1,216,000	1,962,000	3,153,000	5,652,000	7,677,000	9,006,000	8,460,000	9,150,000	10,251,000	10,624,000
interestIncome	267,000	143,000	84,000	659,000	1,116,000	2,652,000	4,402,000	1,787,000	791,000	10,961,000
interestExpense	7,158,000	41,000	2,373,000	5,937,000	10,261,000	13,491,000	13,718,000	13,147,000	3,440,000	3,334,000
incomeBeforeTax	-77,017,000	-80,300,000	-107,147,000	-121,464,000	-48,497,000	-45,942,000	-8,824,000	18,102,000	-52,075,000	-81,846,000
incomeTaxExpense	353,000	382,000	4,434,000	10,381,000	13,165,000	17,617,000	-1,594,000	-1,706,000	6,276,000	10,688,000
netIncome	-77,370,000	-80,682,000	-111,581,000	-131,845,000	-61,662,000	-63,559,000	-7,230,000	19,808,000	-58,351,000	-92,534,000
eps	-1.07	-1.12	-3.67	-1.54	-0.7	-0.69	-0.074	0.2	-0.56	-0.88
epsdiluted	-1.07	-1.12	-3.67	-1.54	-0.7	-0.69	-0.074	0.18	-0.56	-0.88
weightedAverageShsOut	72,137,939	72,137,939	30,401,603	85,558,448	88,546,719	91,828,043	97,237,549	100,930,866	103,433,274	104,660,476
weightedAverageShsOutDil	72,137,939	72,137,939	30,401,603	85,558,448	88,546,719	91,828,043	97,237,549	108,877,648	103,433,274	104,660,476
costAndExpenses	74,818,000	95,646,000	137,083,000	198,205,000	216,354,000	281,741,000	352,232,000	463,965,000	579,364,000	627,363,000
otherExpenses	--	--	--	--	--	--	--	--	--	--

Key Facts

Industry

Medical Instruments & Supplies

Sector

Healthcare

Headquarters

Saint Helier, , JE

Website

novocure.com

CEO

Mr. Asaf Danziger

Employees

1320

About the Company

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.